Tesamorelin

Tesamorelin peptide Canada from Maple Research Labs provides 5mg of research-grade GHRH analog with a published tested 5mg sample report; see the sample-specific results below.

Tesamorelin peptide Canada: a synthetic analog of growth hormone-releasing hormone (GHRH) consisting of 44 amino acids with a trans-3-hexenoic acid modification at the N-terminus. Available from Maple Research Labs at 5mg per vial with published tested-lot documentation; see the sample-specific results below.

Product Specifications

• CAS Number: 218949-48-5
• Structure: Modified GHRH(1-44) analog
• Molecular Weight: Approximately 5135 Da
• Purity: Published 5mg sample report: DBAV-TESA-5-062226 (tested July 9, 2026), HPLC-UV purity 99.14%; expected content 5.00mg, measured content 4.83mg. These results describe the tested 5mg sample, not the 10mg or 20mg options. Documentation for other strengths is not established by this report.
• Form: Lyophilized powder
• Quantity: 5mg per vial

Tesamorelin Peptide Canada Research Summary

Tesamorelin is a synthetic growth hormone-releasing hormone (GHRH) analog that stimulates the anterior pituitary to produce and release growth hormone through the GHRH receptor pathway. The tesamorelin peptide Canada product features the characteristic trans-3-hexenoic acid modification at the tyrosine-1 position, which confers increased resistance to enzymatic degradation compared to native GHRH(1-44).

Unlike direct growth hormone secretagogues that act on the GHSR (ghrelin receptor), tesamorelin operates through the GHRH receptor, stimulating physiological pulsatile GH release patterns. This distinction in mechanism is significant for neuroendocrine research, as GHRH-mediated and ghrelin-mediated GH release involve different signaling cascades and feedback mechanisms.

Mechanism of Action Research

Tesamorelin binds to the GHRH receptor (GHRHR) on somatotroph cells in the anterior pituitary gland. Receptor activation triggers adenylyl cyclase signaling, elevating intracellular cAMP levels and ultimately leading to GH gene transcription, synthesis, and secretion. Because it acts through the pituitary, GH release stays under the normal feedback controls of the GH axis, unlike exogenous GH, which bypasses the pituitary entirely.

The N-terminal hexenoic acid modification protects tesamorelin from dipeptidyl peptidase IV (DPP-IV) cleavage, which rapidly inactivates native GHRH by removing the N-terminal Tyr-Ala dipeptide. This structural modification extends the peptide’s biological half-life while preserving receptor binding affinity and selectivity.

GHRH analogs differ mainly in how their structure is protected from enzymatic breakdown, which changes how long they stimulate the GHRH receptor. Tesamorelin carries a trans-3-hexenoyl group on its full 44-residue sequence; CJC-1295 is a substituted GHRH(1-29) fragment, studied with and without a drug affinity complex (DAC). These structural differences make the compounds useful comparators in neuroendocrine receptor research.

Preclinical Research Summary

In non-clinical studies, tesamorelin (development code TH9507) was resistant to degradation by dipeptidyl peptidase IV and raised circulating growth hormone and IGF-1 levels in rats and dogs (Ferdinandi et al., 2007). In laboratory research it is used as a stabilised GHRH receptor agonist to study somatotroph signalling, cAMP-dependent GH synthesis and secretion, pulsatile release dynamics and regulation of the GH/IGF-1 axis.

All research applications of this product are for laboratory use only. Researchers should consult primary literature for experimental protocols.

References

• Ferdinandi ES, Brazeau P, High K, et al. Non-clinical pharmacology and safety evaluation of TH9507, a human growth hormone-releasing factor analogue. Basic Clin Pharmacol Toxicol. 2007;100(1):49-58 (PubMed)

Tesamorelin Peptide Canada Quality Assurance

Third-party certificates of analysis for tested samples are published on our COA page. The report linked here covers a tested 5mg sample only. HPLC-UV area-percent is a method-specific relative-area result; it does not independently establish molecular identity or sterility, endotoxin status, or safety. Maple vials do not carry printed lot or batch numbers.

Storage and Handling

Store lyophilized at -20C. Avoid freeze-thaw cycles.

Shipping

In-stock orders paid by 2 PM PT (Mon–Fri) ship the same business day, from BC with tracking.

Certificate of Analysis (COA)

For research purposes only. Not for human consumption. Not for diagnostic or therapeutic use.

Related Research Articles

• HGH vs Tesamorelin: Research Comparison
• Ipamorelin vs Tesamorelin: Understanding the Differences
• Certificates of Analysis (COA) Documentation
• Browse All Research Peptides

Frequently Asked Questions

What is the CAS number for Tesamorelin?

The CAS registry number for Tesamorelin is 218949-48-5. It is a synthetic analog of growth hormone-releasing hormone (GHRH).

What is Tesamorelin purity at Maple Research Labs?

Published 5mg sample report: DBAV-TESA-5-062226 (tested July 9, 2026), HPLC-UV purity 99.14%; expected content 5.00mg, measured content 4.83mg. These results describe the tested 5mg sample, not the 10mg or 20mg options. Documentation for other strengths is not established by this report.

How should Tesamorelin be stored?

Lyophilized: -20C. Tesamorelin is a 44-amino acid peptide and should be protected from repeated freeze-thaw cycles.

Related Research Peptides from Maple Research

Researchers may also be interested in CJC-1295 (No DAC), Ipamorelin 5MG, and CJC-1295/Ipamorelin Blend. See each product’s available analytical documentation and tested-sample results in the COA index. In-stock orders paid by 2 PM PT (Mon–Fri) ship the same business day, from BC with tracking.